The overall survival advantage held regardless of PD-L1 status in patients receiving the first-line combination of cadonilimab and standard chemotherapy.
SAN DIEGO — First-line treatment with a combination of cadonilimab, a PD-1/CTLA-4 bispecific immune checkpoint inhibitor, and standard chemotherapy provides a survival advantage over placebo plus chemotherapy in patients with locally advanced or metastatic gastric or gastroesophageal junction adenocarcinoma,, according to a new study.
In a press conference held at AACR 2024, Dr. Ji explained the study rationale, design, and endpoints. He said that patients with tumors without PD-L1 expression typically show little to no benefit from anti–PD-1/PD-L1 inhibitors, and their treatment options are limited to chemotherapy. "In the COMPASSION-15 trial, chemotherapy was stopped after , and only 50% of patients received chemotherapy with subsequent treatment — this is not standard and may limit the comparison with other immunotherapy trials," explained Dr. Janjigian, who is a gastrointestinal oncologist and was a principal investigator in the phase 3 CheckMate 649 immunotherapy trial for advanced gastric cancer.
"The ability of cadonilimab to improve survival outcomes, regardless of PD-L1 status, is a significant advancement, as we have struggled to find effective treatments for patients with low PD-L1 expression in this setting," he said, during the interview.
Noncolorectal Gi Cancer Chemotherapy Combination Chemotherapy Gastric Cancer Malignant Stomach Neoplasm Stomach Cancer Gastric Carcinoma Toxicology Toxicity Poisoning Toxins Cancer Malignant Neoplasia Carcinoma Malignant Neoplasm Biologic Therapy Biologics Antineoplastic Drug Anti-Cancer Agents Erlotinib Gefitinib Imatinib Rituximab Su11248
United States Latest News, United States Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
Ecovacs Deebot X2 Combo vs. Ecovacs Deebot X2 Omni: what’s new on the X2 Combo?The Ecovacs Deebot X2 Combo offers both a robot vacuum and cordless vacuum in one nifty package, but how does it stack up to the older Deebot X2 Omni?
Read more »
Microwave Therapy Shows Similar Progression-Free Survival Rates as Surgery for Thyroid CancerMicrowave therapy had similar progression-free survival rates compared to surgery, which involves removing all or part of the thyroid, results show. It was also less invasive and caused fewer side effects than surgery, researchers added.
Read more »
Personal Perspective: Psychodrama therapy gave me 10 years of therapy in 1 day.A Personal Perspective: Psychodrama is a form of group therapy. Individuals process their childhood traumas by acting out early memories together and rewriting their family stories.
Read more »
Israel's survival is critical to America's survivalBy seeking to diminish Israel, Democrats are playing into the hands of the jihadis for the sake of advancing their religion of the state.
Read more »
Supreme Court prolongs hold on Texas law aimed at undocumented migrantsSupreme Court extends block on Texas law allowing police to arrest migrants suspected of illegal entry, amid ongoing legal battle over immigration authority.
Read more »
New design prolongs the lifespan of plasma torchesThanks to a new design contributed by a research team led by Prof. Zhao Peng from Hefei Institutes of Physical Science (HFIPS) of Chinese Academy of Sciences (CAS), the operation time for plasma torch gas been extended from several days to several years.
Read more »